{
    "clinical_study": {
        "@rank": "73925", 
        "arm_group": [
            {
                "arm_group_label": "APD-209 Eye drops", 
                "arm_group_type": "Active Comparator", 
                "description": "APD-209 Eye drops"
            }, 
            {
                "arm_group_label": "APD-209 Placebo Eye drops", 
                "arm_group_type": "Placebo Comparator", 
                "description": "APD-209 Placebo Eye drops"
            }
        ], 
        "brief_summary": {
            "textblock": "A randomized, double-masked, placebo-controlled, multi-centre phase IIa proof-of-concept\n      study to evaluate efficacy and safety of APD-209 Eye drops for treatment of acute phase\n      adenovirus-induced EKC. The aims of the study are to investigate the therapeutic efficacy of\n      APD-209 Eye drops as measured by adenoviral load, time to viral eradication, clinical\n      resolution of EKC (objective and subjective assessments), presence of opacities, visual\n      acuity and frequency of second eye infections, and to assess the safety and tolerability of\n      APD-209 Eye drops in EKC infected eyes."
        }, 
        "brief_title": "Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC)", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Viral Conjunctivitis", 
        "condition_browse": {
            "mesh_term": [
                "Conjunctivitis", 
                "Conjunctivitis, Viral", 
                "Keratoconjunctivitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        The patients have to meet all of the following criteria to be eligible to enter the study:\n\n          -  Willing and able to provide informed consent.\n\n          -  Men or women aged 18 to 65 years (inclusive) with onset of adenoviral EKC symptoms in\n             at least one eye, as diagnosed by a positive Ad quick test, and with symptoms\n             appearing within less than 48 hours at the time of giving informed consent.\n\n          -  Using adequate contraceptive measures\n\n        Exclusion Criteria:\n\n          -  Known or suspected allergy to any ingredient of the IMP or placebo.\n\n          -  Symptoms correlating with EKC since more than 48 hours.\n\n          -  Diagnosis of other significant disease(s) than EKC in the eye.\n\n          -  Diagnosis of bacterial or fungal ocular infections.\n\n          -  Use of antibiotics or corticosteroids by any route (except intravitreal\n             corticosteroids) within 14 days prior to inclusion.\n\n          -  Use of immunosuppressive medications (including intravitreal corticosteroids) within\n             6 months prior to inclusion.\n\n          -  Use of antiviral medications within 7 days prior to inclusion.\n\n          -  Usage of any medication or herbal medicinal product with documented adverse reactions\n             affecting the eyes.\n\n          -  Usage of any medication or herbal medicinal product for ocular administration at\n             inclusion.\n\n          -  Female patients: currently pregnant or breast-feeding or intending to become pregnant\n             during the study period.\n\n          -  Known or suspected drug abuse.\n\n          -  Usage of contact lenses during the study.\n\n          -  Participation in any other interventional clinical study within 30 days prior to\n             inclusion"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "130", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01977443", 
            "org_study_id": "2012/ADE002", 
            "secondary_id": "2012-005694-31"
        }, 
        "intervention": [
            {
                "arm_group_label": "APD-209 Eye drops", 
                "intervention_name": "APD-209 Eye drops", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "APD-209 Placebo Eye drops", 
                "intervention_name": "APD-209 Placebo Eye drops", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tetrahydrozoline", 
                "Pamidronate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 14, 2013", 
        "location": {
            "contact": {
                "last_name": "Carl Gustaf Laurell, MD PhD"
            }, 
            "facility": {
                "address": {
                    "city": "Stockholm", 
                    "country": "Sweden"
                }, 
                "name": "St Eriks Eye Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "2", 
        "official_title": "Evaluation of the Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Acute Phase Adenoviral-Induced Epidemic Keratoconjunctivitis (EKC). A Randomised, Double-Masked, Placebo-Controlled, Multi-Centre Proof-of-Concept Study", 
        "overall_contact": {
            "email": "bjorn.dellgren@adenovir.com", 
            "last_name": "Bj\u00f6rn Dellgren, M.Sc.", 
            "phone": "+46 (0)42 38 74 28"
        }, 
        "overall_contact_backup": {
            "email": "anita.westintocaj@tfscro.com", 
            "last_name": "Anita Westin Tocaj, Ph.D. M.Sc.", 
            "phone": "+46 (0)46 280 18 00"
        }, 
        "overall_official": {
            "affiliation": "St Eriks Eye Hospital", 
            "last_name": "Carl Gustaf Laurell, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Sweden: Medical Products Agency", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Viral load in tear liquid from EKC infected eyes, as measured by the area under the curve (AUC) at 3-14 days from start of treatment.", 
            "measure": "The primary objective is to assess the adenoviral load in epidemic keratokonjunctivitis (EKC) infected eyes following topical treatment with APD-209 Eye drops compared to placebo.", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01977443"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The time point of viral eradication in tear liquid from EKC infected eyes, defined as the time Point when viral load=0 or below the lower limit of quantification (LLOQ).", 
                "measure": "Assess the time to viral eradication in EKC infected eyes following treatment with APD-209 Eye drops compared to placebo.", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "description": "Resolution of acute ocular symptoms at each time of assessment, as measured by objective (Investigator-based) assessment of conjunctival discharge and redness.", 
                "measure": "Evaluate the effect of APD-209 Eye drops on clinical resolution of EKC, as measured by objective and subjective assessment of scaled clinical symptoms, compared to placebo.", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "description": "Presence and location of opacities at each time of assessment, as measured by slit lamp examination.", 
                "measure": "Evaluate the presence of opacities (quantitatively and qualitatively) following treatment with APD-209 Eye drops compared to placebo.", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "description": "Visual acuity at each time of assessment by use of the logarithm of the Minimum Angle of Resolution (LogMAR) chart.", 
                "measure": "Assess the visual acuity following treatment with APD-209 Eye drops compared to placebo.", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "description": "Occurrence of second eye infection.", 
                "measure": "Assess the frequency of second eye infections.", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "description": "Safety variables: adverse events (AEs) (nature and incidence), Physical examination, vital signs, laboratory safety assessments (haematology, clinical chemistry and urinalysis)", 
                "measure": "Assess the safety and tolerability of APD-209 Eye drops.", 
                "safety_issue": "Yes", 
                "time_frame": "14 days"
            }
        ], 
        "source": "Adenovir Pharma AB", 
        "sponsors": {
            "collaborator": {
                "agency": "TFS AB, Sweden", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Adenovir Pharma AB", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}